American Society of Hematology

SHERPA: Blue

People

  1. Stuver
    Stuver
  2. Horwitz
    Horwitz
  3. Moskowitz
    Moskowitz
  4. Epstein-Peterson
    Epstein-Peterson
  5. Johnson
    Johnson
  6. Hamlin
    Hamlin
  7. Falchi
    Falchi
  8. Kumar
    Kumar
  9. Noy
    Noy
  10. Palomba
    Palomba

Groups

  1. GME, Medicine (50)
  2. Graduate Medical Education (50)
  3. Hematology-Oncology Fellows (50)
  4. Center for Hematologic Malignancies (45)
  5. Department of Medicine (45)
  6. Hematologic Malignancies, Division of (45)
  7. Lymphoma (45)
  8. Population Sciences Research Program (38)
  9. Weinberg Fellows (30)
  10. Sloan Kettering Institute Postdocs (24)
Search Within
  1. "Robert Stuver"
Formats
  1. Meeting Abstract (42)
  2. Journal Article (6)
  3. Review (2)
Groups
  1. GME, Medicine (50)
  2. Graduate Medical Education (50)
  3. Hematology-Oncology Fellows (50)
  4. Center for Hematologic Malignancies (45)
  5. Department of Medicine (45)
  6. Hematologic Malignancies, Division of (45)

More Groups

People
  1. Robert Stuver (50)
  2. Steven Horwitz (38)
  3. Alison Moskowitz (34)
  4. Zachary Epstein-Peterson (26)
  5. William Johnson (24)
  6. Paola Ghione (23)

More People

Years
  1. 2025 (1)
  2. 2024 (20)
  3. 2023 (17)
  4. 2022 (9)
  5. 2021 (3)
Publications
  1. Blood (43)
  2. Blood Advances (6)
  3. Hematology-American Society of Hematology Education Program (1)

Results (50)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from the PETAL consortium
    Journal Article

    Han, J. X.; Koh, M. J.; Boussi, L.; Sorial, M.; McCabe, S. M.; Peng, L.; Singh, S.; Eche-Ugwu, I. J.; Gabler, J.; Fernandez Turizo, M. J.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Sequential R-CHOP/(R)-ICE and dose-adjusted EPOCH-R are both appropriate frontline treatments for newly diagnosed primary mediastinal B-cell lymphoma: Results of a retrospective analysis
    Meeting Abstract

    Bantilan, K. S.; Luttwak, E.; Moskowitz, C. H.; Matasar, M.; Straus, D. J.; Portlock, C. S.; Moskowitz, A.; Noy, A.; Palomba, M. L.; Horwitz, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Angioimmunoblastic versus non-angioimmunoblastic nodal T-follicular helper cell lymphomas: Single center retrospective analysis on 208 cases
    Meeting Abstract

    Sordi, B.; Eren, O. C.; Ganesan, N.; Iyengar, V.; Stuver, R.; Johnson, W. T.; Moskowitz, A.; Ghione, P.; Galasso, N.; Casper, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A prospective geriatric assessment (GA) study predicting toxicities in older adults (OA) with non-Hodgkin Lymphoma (NHL): Timed up and go test (TUG) time emerges as a functional vital sign
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Truong, R.; Qiu, A.; Amador, W. R.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin Lymphoma: A prospective multicenter phase II study
    Meeting Abstract

    Dreyfuss, A.; Ganesan, N.; Alencar, A. J.; Boardman, A. P.; Caron, P.; Chang, T.; Davey, T.; David, K. A.; Dogan, A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improved outcomes for primary refractory classical Hodgkin Lymphoma: A retrospective analysis
    Meeting Abstract

    Santarosa, A. M.; Ganesan, N.; Chang, T.; Hannigan, K.; Casper, E.; Shah, G. L.; Boardman, A. P.; Caron, P.; David, K. A.; Dogan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world outcomes of frontline polatuzumab and impact of frailty in older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Iyengar, V.; Chicola, J.; Joseph, A.; Okwali, M.; Truong, R.; Bapodra, N.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-Year follow up, retreatment outcomes, and Impact of MRD kinetics (ΔMRD400)
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K. L.; Slupe, N.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • High grade B-cell lymphoma with MYC/BCL6-rearrangements (R) may have inferior outcomes compared to BCL2-R disease
    Meeting Abstract

    Healton, S. E.; Luttwak, E.; Rivas-Delgado, A.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Survival and therapeutic outcomes in T-cell prolymphocytic leukemia (T-PLL): A collaborative multi-center study cohort
    Meeting Abstract

    Braunstein, Z.; McLaughlin, E.; Lingamaneni, P.; Barta, S. K.; Cao, M.; Chang, T.; Ganesan, N.; Luu, B.; Mehta-Shah, N.; Shree, T.; more...
    Blood (2024)

    Fulltext@MSK | Save